Comparative Pharmacology
Head-to-head clinical analysis: AMCILL versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCILL versus LAROTID.
AMCILL vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic